Clinical Trial Update: MB-CART2019.1 in Refractory Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for MB-CART2019.1 in refractory multiple sclerosis, currently not yet recruiting in Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MB-CART2019.1

Snippet

Sponsor: Miltenyi Biomedicine GmbH | Conditions: Multiple Sclerosis, CAR T Cell Therapy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING